🧴 Topical Calcineurin Inhibitor vs Steroid Simulator

Topical Steroids — Fast Genomic Anti-Inflammatory Action

Placeholder: steroids bind glucocorticoid receptors and shut down inflammation quickly.

• 1–3 days: Onset time (placeholder value)
• GR: Receptor (glucocorticoid receptor)
• 7: Potency classes (placeholder classes)
• 1–2 wk: Typical course (placeholder duration)

Genomic anti-inflammatory pathway

Placeholder: steroid diffuses into cell, binds GR, alters gene transcription to cut cytokines.

Tacrolimus & Pimecrolimus — Blocking T-Cell Activation

Placeholder: TCIs inhibit calcineurin, blocking IL-2 transcription in T-cells.

• Calcineurin: Target (placeholder enzyme)
• T-cell: Cell type (placeholder target cell)
• ~1 week: Onset time (placeholder value)
• Yes: Steroid-sparing (placeholder note)

T-cell calcineurin blockade

Placeholder: drug binds FKBP, inhibits calcineurin, prevents NFAT-driven cytokine genes.

Comparing Speed of Anti-Inflammatory Onset

Placeholder: steroids relieve symptoms noticeably faster than calcineurin inhibitors.

• Fast: Steroid onset (placeholder comparison)
• Slower: TCI onset (placeholder comparison)
• ~2 wk: Crossover point (placeholder value)
• Variable: Patient adherence (placeholder note)

Onset curve comparison

Placeholder: onset curves diverge early then converge over continued use.

Skin Atrophy vs Application-Site Burning

Placeholder: steroids risk thinning skin, TCIs risk transient burning sensation.

• Rises w/ use: Atrophy risk (steroid) (placeholder trend)
• Early, fades: Burning risk (TCI) (placeholder trend)
• Partial: Reversibility (placeholder note)
• Duration/site: Risk driver (placeholder note)

Side effect trade-off

Placeholder: longer steroid use raises atrophy risk on thin skin; TCIs favor short burning instead.

Choosing Therapy for Face, Eyelids, and Skin Folds

Placeholder: sensitive sites often favor calcineurin inhibitors for long-term maintenance.

• TCI preferred: Face/eyelid pick (placeholder guidance)
• Steroid ok: Body/thick skin (placeholder guidance)
• TCI favored: Maintenance use (placeholder guidance)
• Regular: Monitoring (placeholder note)

Site-specific long-term strategy

Placeholder: match agent to skin site and treatment duration for best long-term outcome.

Placeholder key insight: sensitive-site long-term care generally favors calcineurin inhibitors.